|
Genetic Architecture of Heart Disease in Rural Brazil Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Genetic Architecture of Heart Disease in Rural Brazil conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Genetic Architecture of Heart Disease in Rural Brazil Clinical research trials and Genetic Architecture of Heart Disease in Rural Brazil medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Genetic Architecture of Heart Disease in Rural Brazil. Genetic Architecture of Heart Disease in Rural Brazil Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Genetic Architecture of Heart Disease in Rural Brazil clinical trial. Participants frequently get the best healthcare available for their Genetic Architecture of Heart Disease in Rural Brazil condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Genetic Architecture of Heart Disease in Rural Brazil  Genetic Architecture of Heart Disease in Rural Brazil
Genetic Architecture of Heart Disease in Rural Brazil
For Condition: Chagas Disease,Arrhythmia,Heart Diseases,Heart Failure, Congestive
Status: No longer recruiting
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To examine the genetics of human susceptibility to Chagas' disease, a leading cause of heart disease throughout Latin America.
Details: BACKGROUND: Chagas' disease is a leading cause of heart disease throughout Latin America, affecting between 16 and 18 million individuals. The disease, named after the Brazilian physician Carlos Chagas who first described it in 1909, exists only on the American Continents. It is caused by a flagellate protozoan parasite, Trypanosoma cruzi, transmitted to humans by blood-sucking triatomine insects known popularly in the different countries as "vinchuca", "barbeiro", "chipo" etc. The geographical distribution of the human T.cruzi infection extends from Mexico to the south of Argentina. In Brazil alone, approximately 10 percent of the population is seropositive for T. cruzi. Given the large pool of primary hosts for this zoonotic disease, complete eradication of Chagas' disease through control of the arthropod vector is unlikely. Research with humans and animal models indicates that there is variation in susceptibility to infection, and disease outcome, and that this variation may be due to genetic factors. Thus, this form of heart disease represents a complex phenotype with potential genetic determinants to both susceptibility to infection and differential disease pathogenesis. DESIGN NARRATIVE: The genetic epidemiology project studies an estimated 1,125 Black individuals age 18 years or older from a small community in Posse, Brazil in which the study population may be drawn from as few as four to five large pedigrees with varying blood relationships. Preliminary pilot data appear very promising regarding the primary hypothesis that specific genetic factors influence the susceptibility to this complex zoonotic disease. The investigation will be divided into three parts involving phenotypic characterization, statistical genetic analyses to determine the relative proportion of the phenotypic variance due to additive genetic effects, and localization of genes influencing the development of Chagas' disease. The phenotypic characterization will involve clinical history, infection status, immunologic studies, and cardiac status. The chronic phase of T. cruzi infection results in Chagas' disease manifest as a cardiomyopathy with heart block, conduction disturbance, ventricular tachyarrhythmia, heart failure, and sudden arrhythmic death. The cardiac phenotyping will involve electrocardiographic time intervals (PR interval, QRS duration, QT interval duration) as well as abnormal patterns (left anterior fascicular block, left ventricular hypertrophy, right bundle branch block), and possibly some measure of heart failure in terms of New York Heart Association functional classification. Right bundle branch block is probably the most frequent early manifestation of chronic cardiac involvement. The genetic linkage studies will attempt to localize genes influencing susceptibility to T. cruzi infection, ECG parameters (e.g., right bundle branch block), and immunologic factors using markers placed approximately every 10 centimorgans (cM) throughout the genome. About 375 individuals will be sampled per year. Each subject will donate two 10 ml samples of blood which will be used for immunoassays for seropositivity for T. cruzi, and for genotyping with 382 polymorphic short tandem repeats. During the initial visits, the population subjects will also be interviewed to gather information on demographic, pedigree, and socioeconomic makeup. Additionally, questions on pregnancy status, household ecology (years in the house, rooms shared, pets, rodents, food storage, triatomid bug history, etc) and residence history will be determined during the survey. In the fourth year, the investigators will return to the collection site and administer ECGs on 375 individuals per year. The blood collected in Brazil will be sent to San Antonio for high-throughput genotyping using 382 polymorphic short tandem repeats (STRs) spread throughout the genome. A population specific 10cM map is expected to be useful for linkage analysis.
Eligibility:
Study Type: Observational, Natural History, Cross-Sectional
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: No eligibility criteria
Total Enrollment:
Location and Contact Information:
Overall Study Official:
SarahWilliams-Blangero, , Southwest Foundation for Biomedical Research
Additional Information:
Study ID Numbers: 982;
Study Start Date: September 2001
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00023556
Other Arrhythmia Studies:
1. Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients with Implantable Cardioverter Defibrillators
2. Genetic Determinants of Sudden Cardiac Death
3. Evaluation and Treatment of Heart Disease in Patients not Participating in Research
4. Public Access Defibrillation (PAD) Community Trial
5. Prospective Assessment After Pediatric Cardiac Ablation (PAPCA)
Related Studies:
Other Arrhythmia Clinical Trials
Other Clinical Trials
Other Clinical Trials
Genetic Architecture of Heart Disease in Rural Brazil
|
|
|
|
|
|
|
|
